Alnylam Pharmaceuticals Inc. (ALNY) said that new data from the HELIOS-B Phase 3 study of vutrisiran showed that the drug attenuated ...

Finerenone is at least as effective in patients who are in the hospital or were recently hospitalized for heart failure as those with stable condition, said Akshay Desai, MD, of Brigham & Women’s ...

Endotronix, an Edwards Lifesciences company (NYSE: EW), today announced the one-year clinical results from PROACTIVE-HF, ...

NIH grant fuels research to find improved treatments for heart failure, aiming to advance care and enhance outcomes for ...

Phoenix researcher was recently awarded a $1.9 million National Institutes of Health grant to study the molecular mechanisms of how dilated cardiomyopathy progresses to heart failure, which could ...

A new analysis from SEQUOIA-HCM showed that treatment with aficamten was associated with beneficial changes in five indices reflecting structural, electrophysiologic and biomarker changes in patients ...

Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population Study design intended to ...

Everyone must get the cardiac screening done to detect any abnormalities related to heart health. This article highlights ...

Capricor is planning to start an application seeking the FDA's approval of deramiocel for DMD-related heart disease.

The FDA has extended its approval of UCB’s BIMZELX to three new indications, extending the use of the drug to a total of four ...

Cardiomyopathy occurred in 3.8% of the 1813 TAGRISSO-treated patients ... including assessment of LVEF at baseline and during treatment. For patients receiving TAGRISSO in combination with pemetrexed ...

Standard ALL treatment usually takes between 2 to 3 years. The maintenance phase takes up most of this time as it lasts 2 years. During the maintenance phase people often go back to work or college.